Measurement of urinary N-telopeptides from type I collagen using a colloidal gold-based immunoassay

Journal of Biotechnology

Volumn 153, Issue 3-4, 2011, Pages 176-180

  Lee, Min Ho ^a   Chung, Chin Youb ^b   Lee, Kyoung Min ^b   Seong, Woo Kyeong ^a   Kim, Kyung shik ^c   Lee, Sang Dae ^c   Park, Moon Seok ^b  

^a Korea Electronic Technology Institute (KETI)   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c IM Electronics   (South Korea)

Author keywords

Absorption; Bone turnover marker; Gold nanoparticle; Osteoporosis; Urine N telopeptide

Indexed keywords

ABSORPTION CHANGES; BONE RESORPTION; BONE TURNOVER MARKER; CONFIDENCE INTERVAL; GOLD NANOPARTICLE; GOLD-BASED IMMUNOASSAYS; MEAN AGES; OSTEOPOROSIS; POINT-OF-CARE TESTING; TYPE I COLLAGEN; URINE N-TELOPEPTIDE; URINE SAMPLE;

ABSORPTION; ABSORPTION SPECTROSCOPY; BODY FLUIDS; BONE; GOLD; NANOPARTICLES;

IMMUNOLOGY;

AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLOIDAL GOLD; GOLD NANOPARTICLE;

ADULT; ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SCREENING; SPECTROSCOPY; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN TYPE I; FEMALE; GOLD COLLOID; HUMANS; IMMUNOASSAY; MALE; METAL NANOPARTICLES; MICROSCOPY, ELECTRON, SCANNING; PEPTIDES; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79955754168     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.03.027     Document Type: Article

References (25)

1. Blumsohn A., Hannon R.A., Wrate R., Barton J., Al-Dehaimi A.W., Colwell A., Eastell R. Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. 1994, 40(5):663-670.
2. Bonett D.G. Sample size requirements for estimating intraclass correlations with desired precision. Stat. Med. 2002, 21(9):1331-1335.
3. Braga de Castro Machado A., Hannon R., Eastell R. Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res. 1999, 14(4):602-608.
4. Clemens J.D., Herrick M.V., Singer F.R., Eyre D.R. Evidence that serum NTx (collagen-type 1 N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997, 43(11):2058-2063.
5. El Maghraoui A., Mouinga Abayi D.A., Ghozlani I., Mounach A., Nouijai A., Ghazi M., Achemlal L., Bezza A. Prevalence and risk factors of discordance in diagnosis of osteoporosis using spine and hip bone densitometry. Ann. Rheum. Dis. 2007, 66(2):271-272.
6. Findlay J.W., Dillard R.F. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007, 9(2):E260-267.
7. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature Phys. Sci. 1973, 241:20-22.
8. Garnero P. Biomarkers for osteoporosis management. Mol. Diagn. Ther. 2008, 12(3):157-170.
9. Greenspan S.L., Rosen H.N., Parker R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J. Clin. Endocrinol. Metab. 2000, 85(10):3537-3540.
10. Hanson D.A., Weis M.A.E., Bollen A.-M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 1992, 7(11):1251-1258.
11. Hesley R.P., Shepard K.A., Jenkins D.K., Riggs B.L. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos. Int. 1998, 8(2):159-164.
12. Huber M., Wei T., Muller U.R., Lefebvre P.A., Marla S.S., Bao Y.P. Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. Nucl. Acid. Res. 2004, 32(18):e137.
13. Jennes L., Conn M., Stump W.E. Synthesis and use of colloidal gold coupled receptor ligands. Methods Enzymol. 1986, 124:36-47.
14. Kreibig U., Genzel L. Optical absorption of small metallic particles. Surf. Sci. 1985, 156(2):678-700.
15. Loo C., Hirsch L., Lee M.H., Chang E., West J., Halas N., Drezek R. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt. Lett. 2005, 30(9):1012-1014.
16. Marshall L.A., Cain D.F., Dmowski W.P. Chesnut CHr urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet. Gynecol. 1996, 87(3):350-354.
17. McGraw K.O., Wong S.P. Forming inferences about some intraclass correlation coefficients. Psychol. Methods 1996, 1:30-46.
18. Mora S., Prinster C., Proverbio M.C., Bellini A., De Poli S.C.L., Weber G., Abbiati G., Chiumello G. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif. Tissue Int. 1998, 63:369-374.
19. Nam J., Stoeva S.I., Mirkin C.A. Bio-bar-code-based DNA detection with PCR-like sensitivity. J. Am. Chem. Soc. 2004, 126(19):5932-5933.
20. Raisz L., Smith J.A., Trahiotis M., Fall P., Shoukri K., Digennaro J., Sacco-Gibson N. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos. Int. 2000, 11(7):615-620.
21. Reginster J.Y., Collette J., Neuprez A., Zegels B., Deroisy R., Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008, 42(5):832-836.
22. Rojanathanes R., Sereemaspun A., Pimpha N., Buasorn V., Ekawong P., Wiwanitkit V. Gold nanoparticle as an alternative tool for a urine pregnancy test. Taiwan J. Obstet. Gynecol. 2008, 47(3):296-299.
23. Schultz S., Smith D.R., Mock J.J., Schultz D.A. Single-target molecule detection with nonbleaching multicolor optical immunolabels. PNAS 2000, 97(3):996-1001.
24. Vasikaran S.D., Glendenning P., Morris H.A. The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. Clin. Biochem. Rev. 2006, 27(3):119-121.
25. Zhu X., Han K., Li G. Magnetic nanoparticles applied in electrochemical detection of controllable DNA hybridization. Anal. Chem. 2006, 78(7):2447-2449.